About GeneDx
GeneDx is a publicly listed company based in Stamford (United States) founded in 2017. Genome-based diagnostic solutions for reproductive health and oncology are provided. It operates on a HealthTech and Professional Services model. GeneDx has raised $241 million across 3 funding rounds from investors including Pfizer, Blackstone and BlackRock. GeneDx has completed 2 acquisitions, including GeneDx and LifeMap Solutions. GeneDx offers products and services including ExomeDx, GenomeDx, and GenomeDx Rapid. Its focus areas include Biotechnology and Genetic Testing. Its legal entity is GeneDx, LLC. Its competitors include ArcherDX, Natera and Variantyx; 3 of its 3 listed competitors have raised funding.
Company details
GeneDx is involved in providing advanced genomic and exome testing services to healthcare providers and patients. The company focuses on diagnosing genetic disorders through comprehensive tests like ExomeDx and GenomeDx, targeting conditions such as developmental disorders, epilepsy, autism, and cerebral palsy. Operating in the healthcare and biotechnology sector, GeneDx supports rapid diagnosis for critically ill infants and offers actionable results with clinical expertise. Their solutions are recommended as first-line tests by medical guidelines, aiming to prevent disease progression and improve patient outcomes.
Products & Services of GeneDx
GeneDx offers a comprehensive portfolio of products and services, including ExomeDx, GenomeDx, and GenomeDx Rapid.
Exome sequencing is provided for higher diagnostic yield.
Comprehensive genome sequencing includes mitochondrial genome analysis.
Rapid genome sequencing aids infants in intensive care.
Apps and channels of GeneDx
its YouTube channel GeneDx has 809 subscribers and 30 videos.
Videos from GeneDx
The most watched videos on GeneDx's YouTube channel, GeneDx (809 subscribers). Click a video to play it here.
More on GeneDx.
Funding Insights of GeneDx
GeneDx has successfully raised a total of $241M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $241M
- Total Rounds 3
- Last Round Post-IPO — $200M
- First Round $120M
(Aug 2019)
- Investors Count 8
All 3 funding rounds of GeneDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2022 | $200M | Post-IPO | – | – | |
| Jul 2020 | $121M | Series C | – | BlackRock | |
| Aug 2019 | $120M | Series B | – | Blackstone, Section 32 | – |
8 investors in total: 8 institutional.
Investors in GeneDx
GeneDx has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Blackstone and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Venture capital investments are made in innovative technology startups. | section32.com | |||
Investments are made in early-stage healthtech and fintech startups. | oakhcft.com | Stamford, United States | ||
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 1988 | blackrock.com | New York, United States |
Investor details for GeneDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GeneDx
74 people are tracked at GeneDx (37 in leadership, 6 in board & advisors, 31 in team).
| Name | Role | Group |
|---|---|---|
Shanice W. | Senior Manager, Strategic Finance Business Partner | Leadership |
Lisa Gurry | Chief Business Officer | Leadership |
Megan Marshall | Director, Operations Management And Analytics | Leadership |
Katie Belton | Director, Client Experience - Client Growth & Success | Leadership |
Ashley McQuistan | Associate Director, People Business Partner | Leadership |
Erika Myszynski | Director Of Digital Marketing | Leadership |
Adam Meinel | Head Of Enterprise Applications | Leadership |
Alexandre Fedtsov | Head Of Data Warehouse | Leadership |
Stephanie Kahan | Senior Vice President, Marketing, Communications And Brand | Leadership |
Gabriele Richard | Medical Director | Leadership |
Richard Lusk | Senior Vice President, Growth Finance | Leadership |
Molly Robbins | Director - Process Improvement | Leadership |
Steve McMillan | Head Of Operational Finance | Leadership |
Heather Milligan-Day | Director, Supply & Distribution | Leadership |
Joan Mikardos | Vp, Commercialization And Planning | Leadership |
Audra Bettinelli | Regional Sales Director - South Central | Leadership |
Chaylene Guinto | Head Of Operations Strategy And Analytics | Leadership |
Bryan Dechairo | Chief Operating Officer | Leadership |
Prabhu Devadasan | Sr Director Strategy Forecasting | Leadership |
Paul Newby | VP Of IT | Leadership |
54 more people are available in the full profile.
Complete people profiles for GeneDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GeneDx
GeneDx has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include GeneDx and LifeMap Solutions.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Genetic testing for inherited disorders is provided by the company. | genedx.com | Gaithersburg, United States | 2000 | Jan 2022 | $623M | |
Mobile apps for asthma management | lifemap-solutions.com | San Jose, United States | 2014 | Aug 2017 | •••• |
Complete acquisition details for GeneDx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of GeneDx
6 dated milestones of GeneDx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded GeneDx is founded.
- Acquisition Acquires LifeMap Solutions.
- Funding First funding round of $120.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires GeneDx.
- Funding Latest funding round, Post-IPO, of $200.0M.
Competitors of GeneDx
GeneDx has 3 listed competitors in our database, 3 of them funded. They include ArcherDX, Natera and Variantyx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| variantyx.com | 2014 | Boston, United States | $110.5M | 122 | Genomics data analysis platform for healthcare diagnostics is offered. |
Detailed competitors of GeneDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as GeneDx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genedx
Complete news archive for GeneDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GeneDx
GeneDx was founded in 2017 and raised its 1st funding round 2 years after it was founded.
GeneDx is headquartered in Stamford, United States. It is registered at Stamford, Connecticut, United States.
GeneDx is a funded company, having raised a total of $241M across 3 funding rounds to date. The company's 1st funding round was a Series B of $120M, raised on Aug 2019.
GeneDx is involved in providing advanced genomic and exome testing services to healthcare providers and patients. The company focuses on diagnosing genetic disorders through comprehensive tests like ExomeDx and GenomeDx, targeting conditions such as developmental disorders, epilepsy, autism, and cerebral palsy. Operating in the healthcare and biotechnology sector, GeneDx supports rapid diagnosis for critically ill infants and offers actionable results with clinical expertise. Their solutions are recommended as first-line tests by medical guidelines, aiming to prevent disease progression and improve patient outcomes.
GeneDx offers ExomeDx, GenomeDx, and GenomeDx Rapid.
GeneDx has made 2 acquisitions, including GeneDx, and LifeMap Solutions.
GeneDx has 8 investors. Key investors include Pfizer, Blackstone, BlackRock, Deerfield, and S32.
GeneDx operates through Genedx, Llc.